Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enclomiphene
- Development stage
- Phase 3
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Enclomiphene is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group, developed primarily for the treatment of male secondary hypogonadism. It acts as an estrogen receptor antagonist in the hypothalamus and pituitary gland, blocking negative feedback from estrogen on the hypothalamic-pituitary-gonadal axis. This leads to increased secretion of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH), which together stimulate testicular testosterone production while preserving or enhancing sperm production and fertility. Unlike traditional testosterone replacement therapy, which can suppress natural gonadotropin release and impair fertility, enclomiphene raises serum testosterone levels without these drawbacks. It is one of two stereoisomers of clomifene; specifically, it is the (E)-isomer with more antiestrogenic properties compared to zuclomifene[2][5][6][7].
- Brand names
- AndroxalEnCyzix
- Other names
- enclomiphene citrateEnclomidenclomifene
02
Targets
ER (Estrogen receptor)
Beyond the preview
Go deeper on enclomiphene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enclomiphene.